Expression and clinical significance of programmed cell death protein 1/programmed death-ligand 1 in non-small cell lung cancer patients with rare mutations of epidermal growth factor receptor gene: A retrospective cohort study. [PDF]
CytojournalDu Y, Zhuang Z, Zong L, Xu Y.
europepmc +1 more source
Weitiao No. 3 (3) enhances the efficacy of anti-programmed cell death protein-1 immunotherapy by modulating the intestinal microbiota in an orthotopic model of gastric cancer mice. [PDF]
J Tradit Chin MedXiaona H +7 more
europepmc +1 more source
Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers. [PDF]
World J Gastrointest OncolZhang XM +7 more
europepmc +1 more source
Real-world data confirms limited efficacy of dual programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 immune checkpoint blockade in acral lentiginous melanoma. [PDF]
Br J DermatolZheng DX, Jenkins RW.
europepmc +1 more source
Monocyte/Macrophage-Mediated Transport of Dual-Drug ZIF Nanoplatforms Synergized with Programmed Cell Death Protein-1 Inhibitor Against Microsatellite-Stable Colorectal Cancer. [PDF]
Adv Sci (Weinh)Ye X +11 more
europepmc +1 more source
Related searches:
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
Expert Opinion on Biological Therapy, 2021Introduction: In the past few years, administrating monoclonal humanized antibodies, namely checkpoint inhibitors, against programmed cell death protein 1 (PD-1), and its ligand (PD-L1), has yielded reassuring tumor regression rates. Anti-PD-1/PD-L1 checkpoint inhibitors disrupt the engagement of PD-1 on T-cells and their ligands on tumor or other ...
Parmida Sadat Pezeshki +2 more
openaire +2 more sources
Programmed cell death protein 1 (PD‐1) in infection
APMIS, 2020Exhausted and dysfunctional T cells triggered by infection and cancer render the immune system unable to eliminate these pathogens. Pharmacologic blockade of the surface receptors that inhibit T‐cell function has shown remarkable success in patients with various malignancies.
Steffen, Leth, Søren, Jensen-Fangel
openaire +4 more sources
European Journal of Haematology, 2021 AbstractBackgroundThe programmed cell death protein 1 (PD‐1) and its ligand 1 and 2 (PD‐L1/PD‐L2) regulate the immune system, and the checkpoint pathway can be exploited by malignant cells to evade anti‐tumor immune response. Soluble forms (sPD‐1/sPD‐L1/sPD‐L2) exist in the peripheral blood, but their biological and clinical significance is unclear ...
Julie Bondgaard Mortensen +2 more
exaly +3 more sources
Immunotherapy using programmed cell death 1 protein (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors has been increasingly reported in a variety of nonmelanoma skin cancers (NMSCs).To analyze the evidence of PD-1 and PD-L1 inhibitors in the treatment of NMSC.A primary literature search was conducted with the PubMed, Cochrane Library, EMBASE, Web ...
Franchesca Choi +2 more
exaly +3 more sources
T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas [PDF]
Cancer, 2017 BACKGROUNDPatients with metastatic sarcomas have poor outcomes and although the disease may be amenable to immunotherapies, information regarding the immunologic profiles of soft tissue sarcoma (STS) subtypes is limited.METHODSThe authors identified patients with the common STS subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS ...
Seth M Pollack +2 more
exaly +4 more sources